Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Despite Recent Setbacks, Merck's CV Pipeline Is Strong

This article was originally published in The Pink Sheet Daily

Executive Summary

The Big Pharma reports better than expected first quarter revenues and discusses what is coming in R&D and the cardiovascular pipeline.
Advertisement

Related Content

Merck CEO To Street: Watch For Short-term Adaptability, Long-Term Innovation
Merck Plans To Shed 13% Of Work Force By 2015
Merck Plans To Shed 13% Of Work Force By 2015
Back To The Drawing Board For Portola After Merck Returns Betrixaban
Back To The Drawing Board For Portola After Merck Returns Betrixaban
Phase III Setback For Merck's Antithrombotic Damages One Of The Key Assets Of The Schering Merger
Where Are They Now? Checking In On Four Cardiovascular Start-Ups

Topics

Advertisement
UsernamePublicRestriction

Register

PS072173

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel